SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Sangamo Therapeutics, Inc. SGMO
An SI Board Since April 2000
Posts SubjectMarks Bans Symbol
368 43 0 SGMO
Emcee:  Mike McFarland Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
293Nature Biotechnology 27, 300 (2009) doi:10.1038/nbt0409-300 One-off therapy forenzyme-4/18/2009
292Merriman "Time To Get Back In; News Flow to Drive Stock in 2009; Upgrading bob zagorin-2/5/2009
291Sangamo BioSciences-SGMO is advancing its early-stage pipeline, says Cantor Aftebob zagorin-2/5/2009
290>>However, further analysis of the data has defined the target population tuck-2/5/2009
289Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results bob zagorin-2/4/2009
288Also from Wired (6/08) Gene Editing Could Make Anyone Immune to AIDS By Aaron Rsim1-2/4/2009
287Trial Begins for HIV Gene Therapy By Aaron Rowe [Wired] February 03, 2009 | 7:0sim1-2/4/2009
286Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIVsim1-2/4/2009
285New AIDS approach disrupts patient's DNA <i>[A bit odd not to include tnsaf-2/2/2009
284Recommendations story about SGMO from Cantor After Sangamo reported Phase II datbob zagorin-11/11/2008
283Piper Jaffray Co. Downgrades Sangamo BioSciences (SGMO) to Sell Piper Jaffray Cobob zagorin-11/11/2008
282Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SBsim1-11/10/2008
281Sangamo Presents 'In Vivo' Protection Against HIV Infection by CCR5-ZFN rolatzi-10/28/2008
280Published online 10 September 2008 | Nature 455, 160-164 (2008) | doi:10.1038/4sim1-9/22/2008
279Sigma-Aldrich Launches Breakthrough Genome-Editing Tools Tuesday September 16, 4sim1-9/16/2008
278Sangamo BioSciences Announces Presentation of Data From Diabetic Neuropathy Clinsim1-9/15/2008
277<b>Sangamo's Full Plate of Deals</b> When Big Pharma giants teaGlenn Petersen-8/31/2008
276Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement Wisim1-7/9/2008
275Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use osim1-6/30/2008
274Upcoming Nature Biotech article about HIV resistant Human T cells in mouse Naturolatzi-6/29/2008
273Sangamo BioSciences-SGMO: Unit of DOW exercises commercial ZFP option@LEER Dow Abob zagorin-6/19/2008
272Here's the press release. Dow AgroSciences Announces Early Exercise of Optsim1-6/18/2008
271Hot Stocks story about SGMO, DOW Dow AgroSciences, a wholly owned subsidiary of bob zagorin-6/18/2008
270Sangamo BioSciences-SGMO: Advise buying shares at current levels@LEER The firm abob zagorin-6/11/2008
269Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at Asim1-6/8/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News